Raymond James raised the firm’s price target on Myriad Genetics to $28 from $25 and keeps an Outperform rating on the shares. The full earnings release included some puts and takes, but broadly saw the thesis unchanged, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
- Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
- Myriad Genetics, NCCHE collaborate on SCRUM-MONSTAR-SCREEN-3 study
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024